RxDoctor Payments Data

Alma Lemez, MD

Family Medicine · El Paso, TXNPI 1578568044

Payments from drug & device makers

$2,870in general payments, 2019–2025

Across 120 payments — averaging $23.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$846
  • AstraZeneca$767
  • Pfizer$269
  • Lilly USA, LLC$196
  • Merit Medical Systems Inc$116
  • Novo Nordisk$90
  • plus $587 from 14 others

What the payments were for

  • Food & beverage$2,870100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,870 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$33,771
Medicare patients
91
Services billed
360

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide22$35,999
Omeprazole148$2,552
SynthroidLevothyroxine Sodium20$2,170
Levothyroxine Sodium211$2,151
Atorvastatin Calcium265$2,094
Alendronate Sodium195$1,400
Lisinopril200$1,385
Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid26$1,370
Mirtazapine20$1,329
Metoprolol Succinate112$1,251
Rosuvastatin Calcium67$1,165
Metformin Hcl147$1,058
Olmesartan Medoxomil83$936
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide30$781
Venlafaxine Hcl ErVenlafaxine Hcl18$726

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$196$35,99922 claims
AbbVieSynthroid$846$2,17020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →